Hexima Limited is a biotechnology company actively engaged in the research and development of plant-derived molecules for use in human health and agriculture.


For information relating to investor updates, financial information, share trading and presentations click the link below.


Hexima is developing technology for use in transgenic plants to prevent damage by fungal pathogens and insect pests and for the treatment of fungal infections and non-melanoma skin cancer in humans.

Chairman and CEO update

It is our pleasure to report on an exciting year at Hexima, during which we progressed our lead drug candidate, HXP124, into first-in-human clinical trials. This is a pivotal step in the development of HXP124 as a safe and effective treatment for fungal nail...

Closing Share Price at 30 June 2018

Shares in Hexima Limited are not traded on the ASX.  The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2018, was at the price of $0.08 per share. Download a copy of this announcement...

Hexima doses first patient in phase 1/2a trial of HXP124 as a novel topical treatment for fungal nail infections

Hexima Limited is pleased to announce today that the first patient has been dosed in its phase 1/2a clinical trial of HXP124 in patients with fungal nail infections.

Hexima’s CEO Dr Nicole van der Weerden said “Advancing HXP124 into clinical testing has been a major focus for Hexima through 2017 and we are delighted to have achieved this key milestone. This study will provide important information about the safety of HXP124 and potentially the ability of HXP124 to treat fungal nail infections and is a critical step in the development of this novel topical drug.”

Click on title to read more.

External Links

Take a look at these useful links to learn more about our industry.

Australian Academy of Science
Australian Science Media Centre logo